These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 35134170)

  • 1. Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants.
    Vukajlovic T; Sailer CO; Asmar A; Jensen BL; Vogt DR; Christ-Crain M; Winzeler B
    J Clin Endocrinol Metab; 2022 May; 107(6):e2581-e2589. PubMed ID: 35134170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Glucagon-Like Peptide-1 Receptor Agonists on Hypothalamic-Pituitary-Adrenal Axis in Healthy Volunteers.
    Winzeler B; da Conceição I; Refardt J; Sailer CO; Dutilh G; Christ-Crain M
    J Clin Endocrinol Metab; 2019 Jan; 104(1):202-208. PubMed ID: 30272170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia.
    Winzeler B; Sailer CO; Coynel D; Zanchi D; Vogt DR; Urwyler SA; Refardt J; Christ-Crain M
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34473645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.
    Kan M; Fu H; Xu Y; Yue Z; Du B; Chen Q; Wang X; Yu S; Zhang Z
    Diabetes Obes Metab; 2023 Nov; 25(11):3223-3234. PubMed ID: 37529870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.
    Grunberger G; Chang A; Garcia Soria G; Botros FT; Bsharat R; Milicevic Z
    Diabet Med; 2012 Oct; 29(10):1260-7. PubMed ID: 22804250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System.
    Puglisi S; Rossini A; Poli R; Dughera F; Pia A; Terzolo M; Reimondo G
    Front Endocrinol (Lausanne); 2021; 12():738848. PubMed ID: 34745006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Patel D
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes.
    Ferdinand KC; Dunn J; Nicolay C; Sam F; Blue EK; Wang H
    Cardiovasc Diabetol; 2023 Mar; 22(1):49. PubMed ID: 36894938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
    Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
    Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riesmeyer JS; Riddle MC; Rydén L; Xavier D; Atisso CM; Dyal L; Hall S; Rao-Melacini P; Wong G; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T;
    Lancet; 2019 Jul; 394(10193):121-130. PubMed ID: 31189511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Goldman JD
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
    Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
    Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
    Cukierman-Yaffe T; Gerstein HC; Colhoun HM; Diaz R; García-Pérez LE; Lakshmanan M; Bethel A; Xavier D; Probstfield J; Riddle MC; Rydén L; Atisso CM; Hall S; Rao-Melacini P; Basile J; Cushman WC; Franek E; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T
    Lancet Neurol; 2020 Jul; 19(7):582-590. PubMed ID: 32562683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers.
    Winzeler B; da Conceição I; Refardt J; Sailer CO; Dutilh G; Christ-Crain M
    Endocrine; 2020 Nov; 70(2):292-298. PubMed ID: 32623637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function.
    Wajdlich M; Nowicki M
    Sci Rep; 2024 Feb; 14(1):5002. PubMed ID: 38424466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
    Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Botros FT; Riddle MC; Rydén L; Xavier D; Atisso CM; Dyal L; Hall S; Rao-Melacini P; Wong G; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T;
    Lancet; 2019 Jul; 394(10193):131-138. PubMed ID: 31189509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Renal Extraction and the Natriuretic Action of GLP-1 in Humans Depend on Interaction With the GLP-1 Receptor.
    Asmar A; Cramon PK; Asmar M; Simonsen L; Sorensen CM; Madsbad S; Hartmann B; Holst JJ; Hovind P; Jensen BL; Bülow J
    J Clin Endocrinol Metab; 2021 Jan; 106(1):e11-e19. PubMed ID: 32927478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
    Dagenais GR; Rydén L; Leiter LA; Lakshmanan M; Dyal L; Probstfield JL; Atisso CM; Shaw JE; Conget I; Cushman WC; Lopez-Jaramillo P; Lanas F; Munoz EGC; Pirags V; Pogosova N; Basile J; Sheu WHH; Temelkova-Kurktschiev T; Raubenheimer PJ; Keltai M; Hall S; Pais P; Colhoun HM; Riddle MC; Gerstein HC
    Cardiovasc Diabetol; 2020 Nov; 19(1):199. PubMed ID: 33239067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.